| Hu, Yi |
NCT05649709: Helicobacter Pylori and Vonoprazan Dual Therapy |
|
|
| Completed | 4 | 504 | RoW | L-VA dual therapy, L-VA, H-VA dual therapy, H-VA | The First Affiliated Hospital of Nanchang University | Helicobacter Pylori | 01/24 | 01/24 | | |
public, NCT06162286: A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP |
|
|
| Recruiting | 3 | 100 | RoW | Omadacycline, Moxifloxacin | Zai Lab (Hong Kong), Ltd. | Community-acquired Bacterial Pneumonia | 01/25 | 11/25 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
NCT05509699: Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Surufatinib, Anti-PD-1/L1, Immune checkpoint inhibitor | Hutchison Medipharma Limited | Extensive-Stage Small Cell Lung Cancer | 04/24 | 12/24 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
NCT06512051: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 248 | RoW | SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced or Metastatic Non-small Cell Lung Cancer | 10/26 | 10/26 | | |
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
NCT06349408: IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 250 | RoW | IBI3001 | Innovent Biologics (Suzhou) Co. Ltd. | Locally Advanced Solid Tumor | 12/26 | 12/27 | | |
NCT04368793: Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge |
|
|
| Recruiting | N/A | 200 | RoW | Remote pulmonary rehabilitation | China-Japan Friendship Hospital, Wuhan lung Hospital, Wuhan central hospital, Wuhan University, Ai You Foundation | COVID-2019 Pneumonia, Pulmonary Rehabilitation | 12/20 | 12/21 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
NOR-SPRINT, NCT05291819: Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis |
|
|
| Recruiting | N/A | 202 | Europe | Imaging informed treat-to-target, Conventional treat-to-target | Diakonhjemmet Hospital | Psoriatic Arthritis | 12/27 | 12/27 | | |
NCT05824988: Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease |
|
|
| Recruiting | N/A | 100 | RoW | Drug exposure | Shanghai Pulmonary Hospital, Shanghai, China, Fudan University, University of Sydney, Karolinska Institutet, Shanghai Municipal Center for Disease Control and Prevention | Mycobacterium Avium Complex, Mycobacterium Avium-Intracellulare Infection, Gram-Positive Bacterial Infections, Mycobacterium Infections | 10/25 | 10/26 | | |
| Recruiting | N/A | 15000 | Europe | | Diakonhjemmet Hospital, University Hospital of North Norway, St. Olavs Hospital, Lillehammer Hospital for Rheumatic Diseases, Vestre Viken Hospital Trust, Helse Forde | Inflammatory Joint Diseases | 12/50 | 12/50 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| He, Tao |
NCT03683459: Safety and Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon Catheter |
|
|
| Recruiting | N/A | 208 | RoW | FemFlow Drug-Eluting Peripheral Balloon Catheter | Lifetech Scientific (Shenzhen) Co., Ltd. | Femoral Artery Stenosis, Femoral Artery Occlusion, Popliteal Arterial Stenosis, Popliteal Artery Occlusion | 12/22 | 12/22 | | |
NCT05415995: A Trail of Drug-coated Balloon Treating Below The Knee Arterial Diseases |
|
|
| Recruiting | N/A | 202 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 12/23 | 12/24 | | |
| Gao, Ying |
| Recruiting | 4 | 1200 | RoW | Xingnaojing injection, Xingnaojing placebo injection, Standard care | Dongzhimen Hospital, Beijing, Peking University Third Hospital, Beijing Shuyi Hospital, The Airport Hospital of Shunyi District Beijing, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, The NO.4 People's Hospital of Hengshui, The Second Hospital of Hebei Medical University, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, The Affiliated Hospital of Shaanxi University of Chinese Medicine, Tianshui Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Changzhi Academy of TCM, Zibo Hospital of Traditional Chinese Medicine, Yantai Yuhuangding Hospital, Shandong University of Traditional Chinese Medicine, Zhejiang Provincial Hospital of TCM, Zhejiang Provincial Tongde Hospital, Second Affiliated Hospital of Wenzhou Medical University, People's Hospital of Quzhou, Longhua Hospital, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Taizhou Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Guizhou University of TCM, Guangzhou Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Liling Hospital of Traditional Chinese Medicine, Hunan Academy of Traditional Chinese Medicine Affiliated Hospital, Hubei Hospital of Traditional Chinese Medicine, The First Hospital of Jilin University, Anshan Central Hospital, The Affiliated Hospital of Liaoning University of TCM, The First Hospital of Qiqihar City, Haikou People's Hospital, The Second People's Hospital of Anhui Province, The Third Affiliated Hospital of Shenzhen University, The third people's Hospital of Hubei Province, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, The Third Hospital of Xi'an City | Acute Ischemic Stroke, Stroke, Acute, Stroke, Ischemic | 12/21 | 12/21 | | |
NCT04415164: Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke |
|
|
| Recruiting | 4 | 480 | RoW | Xueshuantong lyophilized powder, Zhusheyong Xueshuantong (donggan), WS-10460(ZD-0460)-2002-2011Z, Placebo, Guidelines-based standard care | Dongzhimen Hospital, Beijing, Tianjin University of Traditional Chinese Medicine | Acute Ischemic Stroke | 10/22 | 05/23 | | |
LIGHT, NCT06653907: Levothyroxine Intervention in Pregnant Women with TSH （2.5 MIU/L-upper Limit of Reference Range） and Negative Thyroid Peroxidase Antibody |
|
|
| Not yet recruiting | 4 | 400 | RoW | Levothyroxine Sodium (LT4) Tablets, Placebo | Yang ZHANG, National Research Institute for Family Planning, China, Fourth Hospital of Shijiazhuang City | Thyroid Abnormalities, Pregnant Woman, Pregnancy Outcomes | 12/26 | 10/27 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
| Recruiting | 2 | 432 | RoW | Buqitongluo Granule, Buqitongluo Granule Placebo, Standard care | Dongzhimen Hospital, Beijing, The Affiliated Hospital of Changchun University of Chinese Medicine, The Affiliated Hospital of Shandong University of Chinese Medicine, The Affiliated Hospital of Chengdu University of Chinese Medicine, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Hunan Academy of Traditional Chinese Medicine Affiliated Hospital, The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine, Shaanxi Buchang Pharmaceuticals Co., Ltd., Beijing Chuanglikechuang Medical Technology Development Co., Ltd., Shanghai Youningwei Biotechnology Co., Ltd., Wuhan Zhizhi Medical Technology Co., Ltd., Wuhan Third Hospital-Tongren Hospital of Wuhan University, Rizhao Hospital of Traditional Chinese Medicine, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Jiangbin Hospital of Guangxi Zhuang Autonomous Region | Stroke, Ischemic, Coronary Artery Disease, Angina Pectoris, Stable, Diabetic Peripheral Neuropathy | 12/22 | 12/22 | | |
NCT06490263: the Safety, Tolerability and Pharmacokinetics of Mulberry Twig Alkaloids in Human |
|
|
| Recruiting | 1 | 68 | RoW | Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects, WH006, Mulberry Twig Alkaloids Tablets with single dose in healthy subjects, Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects, Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects | Beijing Wehand-Bio Pharmaceutical Co., Ltd, Peking University First Hospital | Overweight and Obesity, Healthy | 10/24 | 12/24 | | |
NCT04813445: Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke |
|
|
| Recruiting | N/A | 72 | RoW | Xingnaojing injection | Dongzhimen Hospital, Beijing, Affiliated Hospital of Nantong University, Nanjing Brian Hospital, Affiliated Hospital of Chengde Medical University | Acute Stroke, Ischemic Stroke | 06/22 | 09/22 | | |
NCT06470477: Molecular Characteristics of Phlegm-heat Syndrome in Ischemic Stroke |
|
|
| Not yet recruiting | N/A | 84 | RoW | Guideline-based treatment, Routine care | Dongzhimen Hospital, Beijing | Ischemic Stroke, Acute | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 216 | RoW | Mongolian Medicine ZhenBao Pills, Mongolian Medicine ZhenBao Pills Placebo | Dongzhimen Hospital, Beijing | Ischemic Stroke | 10/25 | 12/25 | | |
| Not yet recruiting | N/A | 20000 | RoW | | Dongzhimen Hospital, Beijing | Ischemic Stroke, Intracerebral Hemorrhage | 12/24 | 06/25 | | |
CARE-TCM, NCT04885374: China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine |
|
|
| Recruiting | N/A | 2000 | RoW | | Dongzhimen Hospital, Beijing | Amyotrophic Lateral Sclerosis | 05/27 | 03/28 | | |
| Zhao, Shi |
NCT05507697: Treatment With Human Umbilical Cord Mesenchymal Stem Cells for Refractory Diabetic Peripheral Neuropathy |
|
|
| Recruiting | 1/2 | 42 | RoW | HUC-MSCs, Lipoic Acid | Wuhan Central Hospital, Wuhan Optics Valley Vcanbio Cell & Gene Technology Co., Ltd., Hubei, China, Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China | Diabetic Peripheral Neuropathy Type 2 | 05/24 | 05/24 | | |
| Chen, Manhua |
| Completed | 3 | 226 | Europe, Canada, US, RoW | Bentracimab (PB2452) Infusion | SFJ Pharmaceuticals, Inc. | Hemorrhage, Urgent Surgery, Invasive Procedure | 09/24 | 09/24 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
| Wang, Hongxiang |
CLL-OBG, NCT05918276: Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL |
|
|
| Not yet recruiting | 2 | 24 | RoW | Orelabrutinib and BG, OBG | Nanfang Hospital of Southern Medical University | CLL/SLL | 12/24 | 12/26 | | |
NCT05672420: Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies |
|
|
| Not yet recruiting | 1/2 | 181 | RoW | umbilical cord derived mesenchymal stem cells | Wuhan Union Hospital, China, Wuhan TongJi Hospital, Wuhan Central Hospital | Hematologic Neoplasms, Neutropenia, Anemia, Thrombocytopenia, Infections, Bleeding | 12/23 | 01/25 | | |
| Recruiting | 1 | 105 | RoW | ICP-248 | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/24 | 10/26 | | |
| Jing, Ping |
NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) |
|
|
| Active, not recruiting | 4 | 2500 | RoW | Sodium Oligomannate Capsules | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 04/25 | | |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
| Guo, Yonglian |
NQTIPS, NCT05551221: The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia |
|
|
| Recruiting | 4 | 312 | RoW | Silodosin Capsules, Qianweitai, Ningmitai capsule, Ningmitai, Tamsulosin | Xintian Pharmaceutical | Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | 12/23 | 12/26 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 472 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
NCT06696794: Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients |
|
|
| Not yet recruiting | 3 | 180 | RoW | Mitomycin C (MMC), Normal Saline (Placebo) | Shaogang Wang | Non-Muscle-Invasive Bladder Cancer (NMIBC) | 06/27 | 06/31 | | |
NCT05545137: Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection |
|
|
| Completed | 3 | 299 | RoW | Pivmecillinam hydrochloride tablets, Selexid®, Fosfomycin Tromethamine Granules, Monurol® | Benova (Tianjin) Innovative medicine Research Co., Ltd. | Uncomplicated Urinary Tract Infection | 02/24 | 02/24 | | |
| Hu, Li-Qun |
| Not yet recruiting | 3 | 8862 | RoW | Colchicine 0.5 mg, no other name, Colchicine 0.375 mg, Placebo | Wuhan Union Hospital, China | Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine | 03/28 | 08/28 | | |
| Sun, Fang |
TQC2731-Ⅱ-04, NCT06707883: A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 258 | RoW | TQC2731 injection, TQC2731 Placebo | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Chronic Obstructive Pulmonary Disease | 12/26 | 09/27 | | |
